Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic And Covidien Continue Shopping In Advance Of Pairing

This article was originally published in The Gray Sheet

Executive Summary

Medtronic and Covidien have announced two deals each in the past week. The two firms are set to be combined by early next year under a megadeal announced in June.

You may also be interested in...



Medtronic Buys Bladder-Control Neurostimulation Firm

Medtronic plans to launch Advanced Uro-Solutions’ 510(k)-cleared Nuro percutaneous tibial nerve stimulation system in the next year following its Feb. 23 acquisition of the firm.

Medtech 2014: M&A, IPOs Bounce Back As Industry Glimpses Future Business Models

Healthy market growth, the biggest ever M&A deal, a record number of billion-dollar takeovers, and the IPO market in impressive bounce-back…2014 was a year of superlatives for the global medtech industry. But with more expected of manufacturers while health care spending remains in the doldrums and demand for care rises, the long-term medtech winners will be those who can forecast how and where to make an impact on both costs and patient outcomes.

Medtech In 2014: M&A, IPOs Bounce Back As Industry Glimpses Future Business Models

Medtech manufacturers saw 2014 as the year of the medtech mega-merger and a rebound in IPOs. But the market is changing, and companies are increasingly cast as service providers who must deliver value.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT033272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel